All In Biotech

Drug Trial Radar · NCT04460547

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

Last checked: Nov 19, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 25, 2020

Primary completion

Aug 15, 2020

Study completion Sep 20, 2020

Sponsor

Lead sponsor
Qassim UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 1 year

Summary

As written by the sponsor on the registry.

On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

Conditions

  • COVID-19

Interventions

  • Convalescent Plasma TransfusionDrug

    Convalescent Plasma Transfusion to COVID-19 infected patients.

  • HydroxychloroquineDrug

    Hydroxychloroquine administration to COVID-19 infected patients.

  • DAS181Drug

    DAS181 administration to COVID-19 infected patients.

  • IvermectinDrug

    Ivermectin administration to COVID-19 infected patients.

  • Interferon Beta-1ADrug

    Interferon Beta-1A administration to COVID-19 infected patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geographical distribution of the interventional studies after 11th of March 2020.Time frame: 15th of August 2020
  2. Geographical distribution of the Observational studies after 11th of March 2020.Time frame: 15th of August 2020
  3. Monthly Research study completion rate as per geographic distribution of the Research.Time frame: 15th of August 2020

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.